title: Reversible posterior leukoencephalopathy syndrome following sunitinib therapy: a case report and review of the literature.
abstract: Sunitinib is one of the standard targeted therapies used in metastatic renal cell carcinoma. It is generally a reasonably tolerated oral systemic therapy but can be occasionally associated with life-threatening toxicities. We present a case of reversible posterior encephalopathy, which is a rare but recognised side effect of the treatment.
authors.affiliation: Drug Development Unit, Royal Marsden Hospital, Sutton, London, United Kingdom. khurum.khan@icr.ac.uk
authors.forename: Khurum H
authors.initials: KH
authors.lastname: Khan
authors.forename: Audrey
authors.initials: A
authors.lastname: Fenton
authors.forename: Eimer
authors.initials: E
authors.lastname: Murtagh
authors.forename: James J A
authors.initials: JJ
authors.lastname: McAleer
authors.forename: Alison
authors.initials: A
authors.lastname: Clayton
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D001921:Brain / Q000473:pathology*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D003937:Diagnosis, Differential; D005260:Female; D006261:Headache / Q000209:etiology; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D054038:Posterior Leukoencephalopathy Syndrome / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis* / Q000473:pathology; D011758:Pyrroles / Q000008:administration & dosage / Q000009:adverse effects*; D012640:Seizures / Q000209:etiology; D000077210:Sunitinib
chemical_list: D020533:Angiogenesis Inhibitors; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib